These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1184 related articles for article (PubMed ID: 27893331)

  • 41. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
    Huang G; Zhai J; Huang X; Zheng D
    Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients.
    Wihandono A; Azhar Y; Abdurahman M; Hidayat S
    Asian Pac J Cancer Prev; 2021 Sep; 22(9):2847-2853. PubMed ID: 34582653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab.
    Al-Hammadi N; AlSabri E; Kudhair AH; Qassam H; Hadi NR
    J Med Life; 2023 Aug; 16(8):1188-1193. PubMed ID: 38024827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers].
    Kanorskiĭ SG; Staritskiĭ AG; Bozhko AA
    Kardiologiia; 2005; 45(3):31-5. PubMed ID: 15821705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
    Jacquinot Q; Paget-Bailly S; Fumoleau P; Romieu G; Pierga JY; Espié M; Lortholary A; Nabholtz JM; Mercier CF; Pauporté I; Henriques J; Pivot X
    Breast; 2018 Oct; 41():1-7. PubMed ID: 29913374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
    Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
    Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
    Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
    Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
    Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
    Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
    Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.
    Narayan HK; Finkelman B; French B; Plappert T; Hyman D; Smith AM; Margulies KB; Ky B
    Circulation; 2017 Apr; 135(15):1397-1412. PubMed ID: 28104715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
    Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
    Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.